BioSante’s GVAX CML Vaccine granted FDA Orphan Drug designation

Published June 8, 2010

BioSante’s GVAX CML Vaccine granted FDA Orphan Drug designation
BioSante Pharmaceuticals, Inc. today announced the receipt of Orphan Drug designation for GVAX CML Vaccine in the treatment of chronic myeloid leukemia (CML) from the FDA’s Office of Orphan Products Development. Orphan drug designation, as granted by the U.S. Orphan Drug Act, is for a product to treat a rare disease or condition that affects fewer than 200,000 people in the U.S. Orphan drug …